Our leadership team brings together cutting-edge expertise in oral biologics with proven commercial and financial leadership to unlock the full potential of advanced therapeutic solutions.
A seasoned leadership team combining deep expertise in oral biologic drug delivery, pharmaceutical development, and biotechnology innovation, with strong commercial and financial leadership to advance high-value biologic therapies from research to real-world impact.
30+ years in biologics and drug delivery. Founder and executive leader advancing innovative oral biologics platforms from discovery through translational
25+ years in drug delivery and biologics development. Led multiple programs across nanoparticles, oral biologics, and IND‑enabling formulation science
35+ years leading global development programs. Directed hundreds of IND and first‑in‑human programs across multiple therapeutic modalities
Indu Javeri is a scientist-entrepreneur specializing in biologics formulation and oral drug delivery technology. She leads corporate strategy, fundraising, and intellectual property development, building a strong oral biologics platform with a defensible patent portfolio. Her focus is on translating scientific innovation into scalable biologic drug delivery solutions with clear value creation for investors and partners.
Kaliappan is an expert in drug delivery systems, protein engineering, and biologics development with over 25 years of experience. He has led multiple programs across nanoparticle systems, liposomes, micelles, and oral biologics platforms, advancing therapies from preclinical stages to IND-enabling development, including oral biologic drug delivery and mRNA lipid nanoparticle technologies.
Stephen has spent the majority of his years as an enterprise leader in commercial roles including Director, V.P., GM/President CCO and CEO roles. Stephen has managed a diverse product portfolio in the life science industry working with lab consumables, bioprocessing capital equipment, CRO/CDMO services and medical device products.
Senior enterprise leader with decades of experience
scaling life‑science businesses, partnerships,
and revenue across global markets
30+ years in biotech finance and governance.
Led capital raises, M&A, and public‑market
finance for global biotech and CRO organizations
L2 Consulting works with an international client base of life science industries in finance, business planning, M&A, program design, executional oversight and interim management.
L2 Consulting works with an international client base of life science industries in finance, business planning, M+A, program design, executional oversight and interim management.
